Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00511238 · ClinicalTrials.gov registry record · Phase 2
Phase 2 Study of Carfilzomib in Relapsed and Refractory Multiple Myeloma
A Phase 2 study, sponsored by Amgen.
- Completed
- Registry status
- Phase 2
- Development phase
- 312
- Enrollment target
NCT00511238: Completed Phase 2 study, sponsored by Amgen.
NCT00511238 is a Phase 2 study that has completed, run by Amgen. The registered enrollment target is 312 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (135% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00511238, a Phase 2 study, has completed, sponsored by Amgen.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 312 participants
- Enrollment target
Study Summary
To evaluate the overall response rate and safety and tolerability of carfilzomib in subjects with relapsed and refractory multiple myeloma. Patients must have received prior treatment with bortezomib and either thalidomide or lenalidomide and be refractory to their last treatment.
Primary Outcome
For both A0 and A1, to evaluate the best overall response rate (stringent complete response \[sCR\]+ complete response \[CR\]+ very good partial response \[VGPR\]+ partial response \[PR\]) in patients with multiple myeloma who had previously received bortezomib and either thalidomide or lenalidomide, had relapsed after two or more therapies, and were refractory to the most recently received therapy
Interventions
- DRUG carfilzomib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 312 participants |
| Start Date | 2007-08 |
| Est. Completion | 2012-10 |
| Phase | Phase 2 |
What the finished NCT00511238 record still lists
NCT00511238 is an interventional study that assigns participants to a tested intervention. The registered 312 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (135% higher).
The record links to 0 conditions, and to 1 intervention - of which carfilzomib is the first listed.
NCT00511238 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00511238 about?
NCT00511238 is a clinical study titled "Phase 2 Study of Carfilzomib in Relapsed and Refractory Multiple Myeloma". To evaluate the overall response rate and safety and tolerability of carfilzomib in subjects with relapsed and refractory multiple myeloma. Patients must have received prior treatment with bortezomib and either thalidomide or lenalidomide and be refractory to their last treatment.
What is the current status of trial NCT00511238?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 312 participants. The study started on 2007-08. Estimated completion is 2012-10.
What interventions are being tested in trial NCT00511238?
The interventions under investigation include: carfilzomib (DRUG).
Who is sponsoring clinical trial NCT00511238?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00511238's enrollment target sits among peer trials
312 161st of 2000 higher than 1,839 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04984551 · 312 participants · Phase 2
Impact of Project ECHO on Improving the Quality of Palliative Care in Patients With Advanced Cancer and Their Caregivers in Underserved Areas of Kenya, Nigeria, Ghana, South Africa, India, and Ethiopia
- NCT04999904 · 312 participants · NA
A Proprioceptive Training Program Using an Uneven Terrain Treadmill for Patients With Ankle Instability
- NCT05220332 · 312 participants · NA
Church-based Intervention to Improve Blood Pressure in African Americans
- NCT05434234 · 312 participants · Phase 1
A Study of YL201 in Patients With Advanced Solid Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia